Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$37.00 USD
+0.70 (1.93%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $37.00 0.00 (0.00%) 5:34 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CLDX 37.00 +0.70(1.93%)
Will CLDX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for CLDX
Celldex’s Barzolvolimab Shows Promise for Urticaria Treatment: A Strong Buy Recommendation
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Celldex announces completion of enrollment in Phase 2 study of barzolvolimab
Jasper Therapeutics initiated with bullish view at Evercore ISI, here's why
Cantor Fitzgerald biotech analysts to hold analyst/industry conference call